Abstract:Background Adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is an autosomal dominant primary microgliopathy caused by kinase loss‐of‐function mutations in the CSF1 receptor (CSF1R). The cardinal features of ALSP include demyelination, axonopathy, and symptoms ranging from frontal temporal dementia‐like behavior, movement disorders, epilepsy, and psychiatric manifestations. Many of these hallmarks further resemble Nasu‐Hakola disease, another rare leukoencephalopathy associated with homozygous mutations in triggering receptor expressed on myeloid cells 2 (TREM2) or its tyrosine kinase binding adaptor (TYROBP) which result in complete loss‐of‐function of TREM2 or its signaling partner DAP12. Following binding to its cognate ligands, IL‐34 or CSF‐1, CSF1R dimerization initiates a signaling cascade both through its kinase domain and through DAP12, which together activate SYK to promote myeloid cell survival, proliferation, and morphological changes. While analogous to CSF1R in cellular expression and interaction with DAP12, TREM2 lacks intrinsic signaling capacity and therefore requires DAP12 to translate extracellular damage‐associated cues and orchestrate a constellation of intracellular and functional responses which phenocopy CSF1R activation. Accordingly, we hypothesize TREM2 activation may rescue CSF1R loss‐of‐function and ameliorate ALSP‐associated pathology. Methods To test whether TREM2 gain‐of‐function could compensate for CSF1R loss‐of‐function, we developed multiple approaches to model ALSP in human myeloid cells by CSF‐1/IL‐34 depletion or CSF1R kinase inhibition using PLX‐5622 and explored functional intervention via a human TREM2 agonistic antibody, VGL101, currently in Phase‐1 clinical development. Rescue for CSF1R was quantified using a combination of live‐cell morphology captured via automated longitudinal microscopy, viability monitored by ATP Cell‐Titer Glo, and apoptosis quantified by Caspase‐3/7 fluorogenic‐imaging. Results In vitro phospho‐SYK profiling of VGL101 in iPSC‐derived microglia is consistent with its agonist profile (EC50: 0.77 ± 0.08 nM), while the absence of pSYK induction in TREM2‐knockout microglia demonstrates exquisite on‐target selectively. In both CSF‐1/IL‐34 depletion and CSF1R kinase inhibition paradigms of ALSP, VGL101 demonstrated full rescue of microglial and monocyte‐derived macrophage viability, inhibited apoptosis, and promoted morphological changes resembling intact CSF1R activation. Conclusion Collectively, our studies support the hypothesis that TREM2 agonism can compensate for CSF1R dysfunction and highlight the therapeutic potential for treating ALSP with TREM2 agonism via VGL101 passive immunotherapy.

Proteolytic Shedding of Human Colony‐Stimulating Factor 1 Receptor and its implication

Identification and Validation of TREM2 in Intracranial Aneurysms

Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Interacts with Colony-Stimulating Factor 1 Receptor (CSF1R) but is Not Necessary for CSF1/CSF1R-Mediated Microglial Survival.

VGL101 Rescues CSF1R Dysfunction in Human Microglia And Macrophages: Evaluation of In Vitro Trem2 Agonism in Models Of A CSF1R‐Dependent Leukodystrophy

Trem2 Enhances Demyelination in the Csf1r+/− Mouse Model of Leukoencephalopathy

Identification of the Minimal Active Soluble TREM2 Sequence for Modulating Microglial Phenotypes and Amyloid Pathology

Opposing Roles of the Triggering Receptor Expressed on Myeloid Cells 2 and Triggering Receptor Expressed on Myeloid Cells-Like Transcript 2 in Microglia Activation.

Dynamic Changes of CSF Strem2 in Preclinical Alzheimer’s Disease: the CABLE Study

Activation of FAK/Rac1/Cdc42‐GTPase Signaling Ameliorates Impaired Microglial Migration Response to Aβ42in Triggering Receptor Expressed on Myeloid Cells 2 Loss‐of‐function Murine Models

The Alzheimers Disease Risk Genes MS4A4A And MS4A6A Cooperate to Negatively Regulate Trem2 and Microglia states

TREM2 Regulates Microglial Cholesterol Metabolism Upon Chronic Phagocytic Challenge

Negative Regulation of TREM2-mediated C9orf72 Poly-Ga Clearance by the NLRP3 Inflammasome

The effect of a dominant kinase-dead Csf1r mutation associated with adult-onset leukoencephalopathy on brain development and neuropathology.

The flexible stalk domain of sTREM2 modulates its interactions with phospholipids in the brain

Soluble TREM2 Induces Inflammatory Responses and Enhances Microglial Survival

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease

Loss of TREM2 diminishes CAA despite an overall increase of amyloid load in Tg-SwDI mice

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways

Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease

Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis